CD30 (TNFRSF8) Antibody Market, Global Outlook and Forecast 2025-2032

MARKET INSIGHTS

Global CD30 (TNFRSF8) Antibody market size was valued at USD 450 million in 2024. The market is projected to grow from USD 510 million in 2025 to USD 1,066 million by 2032, exhibiting a CAGR of 13.4% during the forecast period.

CD30 (TNFRSF8) Antibody is a specialized monoclonal or polyclonal antibody targeting the CD30 protein, which belongs to the tumor necrosis factor receptor superfamily. These antibodies play a crucial role in cancer research and diagnostics, particularly in studying lymphoma and other CD30-positive malignancies. CD30 antibodies are widely used in various applications including flow cytometry, ELISA, western blotting, and immunofluorescence.

The market growth is driven by increasing research in oncology, rising prevalence of lymphomas, and advancements in antibody-based therapeutics. North America currently dominates the market due to strong research funding and presence of key players, while Asia-Pacific is emerging as the fastest-growing region because of expanding biotechnology sector and increasing healthcare investments.

MARKET DYNAMICS

MARKET DRIVERS

Rising Prevalence of Lymphoma to Accelerate Market Growth

The global incidence of lymphoma, particularly Hodgkin's lymphoma and anaplastic large cell lymphoma, continues to rise, creating significant demand for CD30-targeted therapies. CD30 overexpression occurs in approximately 50-60% of Hodgkin lymphoma cases and 70-80% of anaplastic large cell lymphomas. This biomarker specificity makes CD30 antibodies crucial for both diagnostic applications and targeted treatment regimens. The growing biopharmaceutical pipeline featuring CD30-targeted antibody-drug conjugates (ADCs) further underscores its clinical importance, with multiple candidates currently in Phase II/III clinical trials globally.

Advancements in Antibody Engineering Technology to Fuel Innovation

Recent breakthroughs in antibody engineering have significantly enhanced the efficacy of CD30-targeting monoclonal antibodies. Novel conjugation techniques now enable the creation of highly stable antibody-drug conjugates with improved tumor penetration and reduced off-target effects. The development of bispecific antibodies targeting both CD30 and other tumor-associated antigens represents a particularly promising advancement. These technological improvements have led to better clinical outcomes, with recent studies demonstrating response rates exceeding 75% in refractory lymphoma cases when using next-generation CD30-targeting therapies.

Expanding Applications in Immunotherapy to Drive Adoption

CD30 antibodies are finding increasing utility in the rapidly growing field of cancer immunotherapy. Beyond their traditional diagnostic role, these antibodies now contribute to innovative treatment modalities including chimeric antigen receptor (CAR) T-cell therapies and immune checkpoint modulation. The versatility of CD30 as a therapeutic target has attracted substantial research investments, with global funding for CD30-related immunotherapy projects growing at approximately 18% annually since 2020. This expansion into new therapeutic areas continues to create new revenue streams for market participants.

MARKET RESTRAINTS

High Treatment Costs to Limit Market Penetration

The premium pricing of CD30-targeted therapies, particularly antibody-drug conjugates, poses a significant barrier to widespread adoption. Current CD30-based treatments can exceed $150,000 per annual regimen, placing them beyond the reach of many healthcare systems and patients in price-sensitive markets. This economic constraint is particularly pronounced in developing regions where healthcare budgets remain limited.

Additional Restraints

Tumor Heterogeneity Challenges
Variability in CD30 expression patterns across tumor types and even within individual tumors creates diagnostic and therapeutic challenges. Approximately 20-30% of CD30-positive tumors demonstrate heterogeneous antigen expression, potentially compromising treatment efficacy and necessitating combination therapies that increase both complexity and cost.

Safety Concerns
The immunogenicity of therapeutic antibodies remains an ongoing concern, with infusion reactions and off-target effects reported in clinical settings. Balancing therapeutic efficacy with acceptable safety profiles continues to require extensive clinical testing and monitoring, increasing both development timelines and regulatory scrutiny.

MARKET OPPORTUNITIES

Emerging Markets to Offer Untapped Growth Potential

Developing economies represent a significant growth opportunity as healthcare infrastructure improvements and rising cancer awareness drive demand for advanced diagnostics and therapies. The Asia-Pacific region in particular demonstrates strong potential, with projected CAGR exceeding 18% through 2030. Local manufacturing initiatives and strategic partnerships between multinational pharmaceutical companies and regional players are accelerating market development.

Companion Diagnostics Development to Create New Revenue Streams

The growing emphasis on precision medicine is driving demand for CD30-specific companion diagnostics. These tests enable clinicians to identify patients most likely to benefit from targeted therapies, improving treatment outcomes while optimizing healthcare resource allocation. The companion diagnostics segment is projected to grow at 21% annually through 2030, presenting attractive opportunities for diagnostic manufacturers.

Biosimilar Development to Enhance Market Accessibility

The impending patent expiry of major CD30-targeted biologics is expected to stimulate biosimilar development, potentially reducing treatment costs by 30-40%. Several biopharmaceutical companies have already initiated biosimilar development programs, with first approvals anticipated in key markets by 2026. This development trajectory aligns with global trends toward more affordable biologic therapies.

MARKET CHALLENGES

Regulatory Complexity to Increase Development Timelines

The approval pathway for CD30-targeted therapies remains complex, often requiring extensive clinical data packages to demonstrate both safety and efficacy. Regulatory agencies continue to raise evidence requirements, particularly for novel antibody formats and combination therapies. These requirements frequently extend development cycles by 12-18 months compared to traditional small molecule drugs.

Additional Challenges

Cold Chain Logistics
The temperature-sensitive nature of antibody-based products necessitates sophisticated cold chain infrastructure, presenting distribution challenges in regions with limited logistics capabilities. Maintaining product integrity throughout the supply chain adds approximately 15-20% to overall distribution costs.

Reimbursement Hurdles
Healthcare payers increasingly demand robust cost-effectiveness data before providing coverage for novel targeted therapies. The health economics and outcomes research required to meet these evidentiary standards represents a significant investment for manufacturers, potentially delaying market access.

Segment Analysis:

By Type

Monoclonal Antibody Segment Leads Due to High Specificity in Research and Clinical Applications

The market is segmented based on type into:

• Monoclonal Antibody

• Polyclonal Antibody

By Application

Flow Cytometry Dominates Owing to Widespread Use in Cancer Research and Immunophenotyping

The market is segmented based on application into:

• Flow Cytometry

• ELISA

• Western Blot

• Immunofluorescence

• Others

By End User

Pharmaceutical and Biotechnology Companies Drive Demand Through Drug Development

The market is segmented based on end user into:

• Pharmaceutical and Biotechnology Companies

• Research Institutes

• Diagnostic Laboratories

• Academic Institutions

COMPETITIVE LANDSCAPE

Key Industry Players

Market Leaders Expand Therapeutic Antibody Development in High-Growth Segment

The global CD30 (TNFRSF8) antibody market features a competitive but fragmented structure, with key players leveraging their expertise in oncology research and diagnostic applications. Sino Biological, Inc. and Bio-Techne currently dominate the supplier space, accounting for approximately 28% of total market revenue in 2024 through their comprehensive antibody portfolios targeting both research and clinical applications.

Emerging players are gaining traction through specialization - Boster Biological Technology has captured significant market share in Asia through competitively priced ELISA kits, while Cell Signaling Technology, Inc. maintains premium positioning through its rigorously validated antibodies for Western blot applications. This diversification creates dynamic pricing pressures across different market segments.

The competitive intensity is further heightened by recent strategic moves. Thermo Fisher Scientific strengthened its position through the 2023 acquisition of a CD30 antibody production facility in Massachusetts, while Merck KGaA invested €50 million in expanding its Frankfurt-based antibody development center. Such capacity expansions signal the industry's bullish long-term outlook despite current pricing challenges.

List of Key CD30 (TNFRSF8) Antibody Manufacturers

• Sino Biological, Inc. (China)
• Bio-Techne (U.S.)
• Thermo Fisher Scientific (China) Co., Ltd. (U.S.)
• Boster Biological Technology (U.S.)
• MyBiosource, Inc. (U.S.)
• Abeomics Inc. (U.S.)
• Abbexa (U.K.)
• Cell Signaling Technology, Inc. (U.S.)
• Creative Diagnostics (U.S.)
• OriGene Technologies, Inc. (U.S.)
• Merck KGaA (Germany)
• Cayman Chemical (U.S.)
• CUSABIO (China)
• Biotium (U.S.)
• BioLegend (U.S.)
• Abcepta (U.S.)
• ProSci Incorporated (U.S.)

Regional dynamics notably influence market competition, with Chinese manufacturers gaining share through government-supported biotechnology initiatives. However, North American and European firms maintain technology leadership in high-value therapeutic antibody development, particularly for lymphoma treatment applications. This geographical specialization creates distinct competitive arenas across the value chain.

CD30 (TNFRSF8) ANTIBODY MARKET TRENDS

Rising Prevalence of Lymphomas Drives CD30 Antibody Market Expansion

The global CD30 (TNFRSF8) antibody market is experiencing a robust 13.4% CAGR, propelled by increasing lymphoma diagnoses and targeted therapy adoption. With over 80,000 new cases of Hodgkin lymphoma diagnosed annually worldwide - where CD30 is expressed in nearly all cases - demand for diagnostic and therapeutic antibodies continues to climb. Recent industry reports indicate North American hospitals now use CD30 diagnostics in 68% of suspected lymphoma cases, compared to just 45% five years ago. This trend is accelerating as novel antibody-drug conjugates like brentuximab vedotin demonstrate response rates exceeding 70% in relapsed Hodgkin lymphoma cases, validating CD30's therapeutic potential.

Other Trends

Technological Advancements in Antibody Production

The market is witnessing a shift toward recombinant antibody technologies, with monoclonal antibodies capturing 82% of 2024 market share due to their superior specificity. Protein engineering breakthroughs now enable 95% pure antibody yields in mammalian expression systems, reducing production costs by approximately 30% since 2020. Concurrently, innovative conjugation techniques are enhancing antibody-drug conjugate efficacy while minimizing off-target effects - a critical development as 85% of ongoing CD30 clinical trials now involve conjugated antibody formats.

Expanding Applications in Companion Diagnostics

CD30 antibodies are gaining traction as essential tools for precision oncology, with flow cytometry applications growing at 17.2% annually - the fastest among all diagnostic segments. Pharmaceutical companies are increasingly incorporating CD30 testing into drug development protocols, as 42% of new lymphoma drug candidates now require companion diagnostics. The immunofluorescence segment, while currently holding just 12% market share, is projected to triple by 2032 as multiplex imaging technologies enable simultaneous detection of multiple tumor markers. This expansion is further supported by regulatory approvals of 15 new CD30-based IVD products in the past two years across major markets.

Regional Analysis: CD30 (TNFRSF8) Antibody Market

North America
North America dominates the CD30 (TNFRSF8) Antibody market, accounting for approximately 38% of global revenue in 2024. The region's leadership stems from advanced healthcare infrastructure, significant R&D investments in oncology therapeutics, and high adoption of targeted cancer treatments. The U.S. FDA's accelerated approval pathways for antibody-based therapies, such as brentuximab vedotin (an anti-CD30 antibody-drug conjugate), further drive market growth. However, stringent regulatory requirements and pricing pressures pose challenges for new entrants. Key research institutions and pharmaceutical companies are increasingly collaborating on CD30-targeted immunotherapies, reflecting the region's focus on precision medicine.

Europe
Europe represents the second-largest market for CD30 antibodies, with Germany and the U.K. contributing over 45% of regional sales. The European Medicines Agency's (EMA) supportive regulatory framework for orphan drug designation has encouraged development of CD30-targeted therapies for rare lymphomas. While Western European countries show strong adoption due to established healthcare systems, Eastern Europe lags behind due to budget constraints in public healthcare. Recent clinical trials exploring combination therapies using CD30 antibodies with checkpoint inhibitors highlight the region's innovative approach. However, pricing transparency initiatives and mandatory discount policies may constrain profit margins for manufacturers.

Asia-Pacific
Asia-Pacific is projected to be the fastest-growing market, with an estimated CAGR of 15.2% through 2032. China's growing cancer burden and expansion of biopharma capabilities account for nearly 60% of regional demand. While Japan leads in per capita spending on biologics, India's emerging contract research organizations are driving down antibody production costs. The lack of harmonized regulations across ASEAN countries creates logistical challenges, but increasing healthcare expenditure and rising awareness about targeted cancer therapies present long-term opportunities. Local manufacturers are gaining traction by offering cost-effective alternatives to Western brands.

South America
South America's market remains nascent but shows gradual growth, particularly in Brazil which constitutes over 65% of regional revenue. Economic instability and currency fluctuations impact the procurement of expensive biologic drugs, leading to preference for biosimilars. Public healthcare systems struggle with reimbursement for targeted therapies, though private oncology centers in urban areas demonstrate higher adoption rates. Recent trade agreements facilitating technology transfer in Argentina and Chile may stimulate local production capabilities. The lack of specialized cancer registries and delayed regulatory approvals continue to hinder market expansion across the region.

Middle East & Africa
This region represents the smallest but most dynamic emerging market, with the UAE and South Africa accounting for 80% of CD30 antibody utilization. While wealthy Gulf nations import premium-priced biologics through hospital tenders, Sub-Saharan Africa primarily relies on donor-funded programs and generic versions. Turkey's growing biotech sector shows potential for local CD30 antibody production. However, limited healthcare access in rural areas, inadequate cold chain logistics, and political instability in certain countries constrain consistent market growth. The increasing prevalence of HIV-associated lymphomas presents both clinical need and commercial opportunity for targeted therapies.

Report Scope

This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2032. It presents accurate and actionable insights based on a blend of primary and secondary research.

Key Coverage Areas:

• ✅ Market Overview

  • Global and regional market size (historical & forecast)

  • Growth trends and value/volume projections

• ✅ Segmentation Analysis

  • By product type or category

  • By application or usage area

  • By end-user industry

  • By distribution channel (if applicable)

• ✅ Regional Insights

  • North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

  • Country-level data for key markets

• ✅ Competitive Landscape

  • Company profiles and market share analysis

  • Key strategies: M&A, partnerships, expansions

  • Product portfolio and pricing strategies

• ✅ Technology & Innovation

  • Emerging technologies and R&D trends

  • Automation, digitalization, sustainability initiatives

  • Impact of AI, IoT, or other disruptors (where applicable)

• ✅ Market Dynamics

  • Key drivers supporting market growth

  • Restraints and potential risk factors

  • Supply chain trends and challenges

• ✅ Opportunities & Recommendations

  • High-growth segments

  • Investment hotspots

  • Strategic suggestions for stakeholders

• ✅ Stakeholder Insights

  • Target audience includes manufacturers, suppliers, distributors, investors, regulators, and policymakers

FREQUENTLY ASKED QUESTIONS:

What is the current market size of Global CD30 (TNFRSF8) Antibody Market?

-> The Global CD30 (TNFRSF8) Antibody market was valued at USD 450 million in 2024 and is projected to reach USD 1066 million by 2032, growing at a CAGR of 13.4% during the forecast period.

Which key companies operate in Global CD30 (TNFRSF8) Antibody Market?

-> Key players include Sino Biological, Inc., Bio-Techne, Thermo Fisher Scientific, Merck, Cell Signaling Technology, BioLegend, and Abbexa, among others.

What are the key growth drivers?

-> Key growth drivers include rising prevalence of lymphomas, increasing R&D investments in oncology, and advancements in antibody-based therapeutics.

Which region dominates the market?

-> North America currently holds the largest market share, while Asia-Pacific is expected to witness the fastest growth during the forecast period.

What are the emerging trends?

-> Emerging trends include development of novel antibody-drug conjugates, increasing adoption of companion diagnostics, and growing focus on targeted cancer therapies.